Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib

May 2013 in “ Journal of Clinical Oncology ”

Yi‐Hsien Shih, Pin-Chun Chen, Chia‐Yu Chu

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on ascopubs.org →

Discuss this study in the Community →

Cited in this study

2 / 2 results

research Folliculitis Decalvans Associated with Erlotinib

25 citations, April 2010 in “Clinical and Experimental Dermatology”

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

research Two Distinct Signaling Pathways in Hair Cycle Induction: Stat3-Dependent and Independent Pathways

73 citations, November 2000 in “Proceedings of the National Academy of Sciences of the United States of America”

There are two ways to start hair growth: one needs Stat3 and the other does not, but both need PI3K activation.